QCG
RCUS icon

Quadrant Capital Group’s Arcus Biosciences RCUS Stock Holding History

Quadrant Capital Group’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,088
Closed -$23.5K – 2265
2026
Q1 		$23.5K Buy
1,088
+9
+0.8% +$194 ﹤0.01% 1951
2025
Q4 		$25.7K Hold
1,079
– – ﹤0.01% 1910
2025
Q3 		$14.7K Buy
+1,079
New +$11.2K ﹤0.01% 2048
2025
Q2 		– Sell
-3,721
Closed -$29.2K – 2306
2025
Q1 		$29.2K Buy
3,721
+3,643
+4,671% +$42.2K ﹤0.01% 1911
2024
Q4 		$1.16K Sell
78
-57
-42% -$931 ﹤0.01% 2575
2024
Q3 		$2.06K Sell
135
-13
-9% -$205 ﹤0.01% 2494
2024
Q2 		$2.25K Sell
148
-5
-3% -$81 ﹤0.01% 2455
2024
Q1 		$2.89K Sell
153
-288
-65% -$4.98K ﹤0.01% 2434
2023
Q4 		$8.42K Sell
441
-181
-29% -$2.89K ﹤0.01% 2129
2023
Q3 		$11.2K Buy
622
+53
+9% +$1.06K ﹤0.01% 1943
2023
Q2 		$11.6K Buy
569
+300
+112% +$5.71K ﹤0.01% 1940
2023
Q1 		$4.91K Sell
269
-86
-24% -$1.64K ﹤0.01% 2243
2022
Q4 		$7.34K Buy
355
+114
+47% +$3.14K ﹤0.01% 2092
2022
Q3 		$6K Buy
241
+223
+1,239% +$5.9K ﹤0.01% 2089
2022
Q2 		$0 Buy
+18
New +$441 ﹤0.01% 2691

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Quadrant Capital Group's RCUS Position: Q2 2026 in Review

Quadrant Capital Group sold out of Arcus Biosciences (RCUS) in Q2 2026, closing a stake of 1,088 shares — an estimated $23.5K sold.

Quadrant Capital Group first reported a position in RCUS in Q2 2022 and held it in 15 quarters. The position peaked at $29.2K in Q1 2025. 231 funds tracked by Wall St. Rank hold RCUS as of Q2 2026.

  • Quadrant Capital Group reported no remaining Arcus Biosciences position as of Q2 2026 after selling out during the quarter.
  • Quadrant Capital Group sold 1,088 Arcus Biosciences shares in Q2 2026, an estimated $23.5K.
  • Quadrant Capital Group first reported a position in Arcus Biosciences in Q2 2022 and held it in 15 quarters.
  • Quadrant Capital Group's Arcus Biosciences position peaked at $29.2K in Q1 2025.
  • 231 funds tracked by Wall St. Rank held Arcus Biosciences as of Q2 2026.

Based on Quadrant Capital Group's 13F filing for Q2 2026, filed 14 Aug 2026.